Arrowhead Pharmaceuticals Soars to New High on Plozasiran Expansion Plans

Arrowhead Pharmaceuticals (ARWR) surged 28% to a five-year high of $95.49 after announcing plans to submit a supplemental new drug application (sNDA) for plozasiran to treat severe hypertriglyceridemia by end of 2026. The drug, already approved as Redemplo for familial chylomicronemia syndrome (FCS) in the US, Europe, Australia, and Canada, showed strong Phase 3 results: 79-81% reduction in triglycerides and 78% reduction in acute pancreatitis cases versus placebo. The company will report Q3 earnings on August 4, 2026, and present detailed Phase 3 data at ESC 2026 on August 30. Despite the positive news, hedge fund conviction softened, with combined holdings declining 8.9% to $1.74 billion quarter-over-quarter.

First published Aug 4, 01:58 PM UTCUpdated Jul 22, 07:05 PM UTC1 reports · 1 sources

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
Page status: Current automated evidence projection
Last updated: Jul 22, 07:05 PM UTCEditorial record as of Aug 4, 01:58 PM UTC

How automation and AI are used · Report a correction or rights issue

Wire timeline

currentJul 22, 07:05 PM UTC

Arrowhead Pharmaceuticals Soars to New High on Plozasiran Expansion Plans

Coverage sources

External reporting used to assemble this Story.

Arrowhead Pharmaceuticals Soars to New High on Plozasiran Expansion PlansYahoo FinanceWesternJul 22, 07:05 PM UTC

Follow the context

Food and Drug Administration